MeSH term
Frequency | Condition_Probility | Humans | 44 | 0.0 |
Adult | 10 | 0.0 |
Animals | 12 | 0.0 |
Mice | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 15 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 16 | 0.0 |
Signal Transduction | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Aged | 6 | 0.0 |
Cholesterol/blood | 2 | 0.0 |
Comparative Study | 4 | 0.0 |
English Abstract | 9 | 0.0 |
Female | 16 | 0.0 |
Middle Aged | 9 | 0.0 |
Time Factors | 3 | 0.0 |
*Receptors, G-Protein-Coupled | 4 | 1.0 |
Receptors, Lysophosphatidic Acid | 4 | 9.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Separation | 2 | 0.0 |
Male | 16 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
3T3 Cells | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Adolescent | 5 | 0.0 |
Arteriosclerosis/etiology | 2 | 2.0 |
Risk Factors | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Lipoproteins/*blood | 3 | 0.0 |
Phenotype | 2 | 0.0 |
*Adrenalectomy | 2 | 18.0 |
*Laparoscopy | 2 | 11.0 |
Renal Circulation | 3 | 8.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Rats | 3 | 0.0 |
Histocytochemistry | 3 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Apolipoprotein A-II | 2 | 4.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Lectins/metabolism | 2 | 2.0 |
Receptors, Mitogen/*analysis | 2 | 20.0 |
Apolipoproteins A/*blood | 2 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Ultracentrifugation | 2 | 1.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Lipoproteins, HDL/*blood | 3 | 1.0 |
Models, Biological | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
